Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.
Aerovate Therapeutics Trading Down 0.4 %
NASDAQ:AVTE traded down $0.01 during trading hours on Monday, hitting $2.46. The stock had a trading volume of 60,056 shares, compared to its average volume of 581,241. The company has a market cap of $71.03 million, a PE ratio of -0.82 and a beta of 1.01. The business has a 50 day simple moving average of $2.50 and a two-hundred day simple moving average of $2.40. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
